Cardiotoxicity of Immune Checkpoint Inhibitors

PURPOSE OF REVIEW: Immune checkpoint inhibitors (ICIs) have improved the survival of several cancers. However, they may cause a wide range of immune-related adverse events (irAEs). While most irAEs are manageable with temporary cessation of ICI and immunosuppression, cardiovascular toxicity can be a...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Rushin P., Parikh, Rohan, Gunturu, Krishna S., Tariq, Rana Zouveenoor, Dani, Sourbha S., Ganatra, Sarju, Nohria, Anju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Cardio-oncology (EH Yang, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088903/
https://www.ncbi.nlm.nih.gov/pubmed/33937956
http://dx.doi.org/10.1007/s11912-021-01070-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088903/
https://www.ncbi.nlm.nih.gov/pubmed/33937956
http://dx.doi.org/10.1007/s11912-021-01070-6

Ejemplares similares